VanEck Biotech ETF (BBH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VanEck Biotech ETF (BBH) trades at $237.11 with AI Score 47/100 (Grade C). VanEck Biotech ETF (BBH) aims to mirror the MVIS US Listed Biotech 25 Index, focusing on companies involved in genetic analysis-based… Market cap: $457M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for BBH: BBH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BBH against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BBH: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
VanEck Biotech ETF (BBH) Financial Services Profile
VanEck Biotech ETF (BBH) provides targeted exposure to the biotechnology sector by replicating the MVIS US Listed Biotech 25 Index. It focuses on companies involved in genetic analysis, drug development, and diagnostic equipment, offering investors a specialized investment vehicle within the broader financial services landscape.
What Is the Investment Thesis for BBH?
VanEck Biotech ETF (BBH) presents a targeted investment opportunity in the biotechnology sector, driven by innovation in genetic analysis and drug development. The ETF's strategy of mirroring the MVIS US Listed Biotech 25 Index offers exposure to leading biotech companies. A key value driver is the continued growth in the biotechnology industry, fueled by advancements in genomics and personalized medicine. Upcoming catalysts include potential breakthroughs in drug development and regulatory approvals for new therapies. The ETF's beta of 0.79 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors. However, potential risks include regulatory hurdles, clinical trial failures, and competitive pressures within the biotech industry. The absence of a dividend yield may deter income-focused investors.
Based on FMP financials and quantitative analysis
BBH Key Highlights
Market Cap of $457M indicates the fund's size and potential liquidity.
- Beta of 0.79 suggests lower volatility compared to the broader market.
- Focus on the MVIS US Listed Biotech 25 Index provides targeted exposure to leading biotech companies.
- Absence of dividend yield may not appeal to income-focused investors.
- Exposure to companies involved in genetic analysis and diagnostic equipment offers potential for growth driven by innovation in biotechnology.
Who Are BBH's Competitors?
BBH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUX Bluemonte Dynamic Total Market ETF | $32.47 | -0.93% | $579M | 44 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $47.53 | +0.02% | $368M | 47 |
| DDEC FT Vest U.S. Equity Deep Buffer ETF - December | $48.20 | -0.19% | $365M | 47 |
| DJAN FT Vest U.S. Equity Deep Buffer ETF - January | $46.27 | -0.23% | $372M | 47 |
| DJD Invesco Dow Jones Industrial Average Dividend ETF | $65.63 | -1.23% | $470M | 47 |
| SOR Source Capital, Inc. | $46.29 | -0.92% | $381M | 71 |
| NCDL Nuveen Churchill Direct Lending Corp. | $12.35 | +0.00% | $610M | 86 |
| CAF Morgan Stanley China A Share Fund, Inc. | $19.33 | -1.23% | $325M | 87 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BBH's Key Strengths?
Targeted exposure to the biotechnology sector.
- Replicates a well-established index (MVIS US Listed Biotech 25 Index).
- Managed by a reputable investment management firm (VanEck).
- Provides diversification within the biotech industry.
What Are BBH's Weaknesses?
Subject to the volatility of the biotechnology sector.
- Performance is dependent on the performance of the underlying index.
- Absence of dividend yield may not appeal to all investors.
- Concentrated exposure to a specific sector.
What Could Drive BBH Stock Higher?
Potential breakthroughs in drug development and regulatory approvals for new therapies.
- Advancements in genomics and personalized medicine driving growth in the biotechnology sector.
- Increasing demand for biopharmaceuticals due to the aging global population and rising prevalence of chronic diseases.
- Strategic acquisitions and partnerships within the biotechnology sector.
What Are the Key Risks for BBH?
Regulatory hurdles and clinical trial failures can negatively impact the performance of biotech companies.
- Competitive pressures within the biotechnology industry can erode market share and profitability.
- Economic downturns and market volatility can negatively impact the value of biotech stocks.
- Changes in government regulations and healthcare policies can impact the biotechnology sector.
- The biotechnology sector is subject to rapid technological advancements, which can render existing therapies obsolete.
What Are the Growth Opportunities for BBH?
- Growth opportunity 1: Advancements in Genomics and Personalized Medicine: The increasing focus on personalized medicine, driven by advancements in genomics, creates significant growth opportunities for companies within the biotechnology sector. BBH, with its exposure to companies involved in genetic analysis and drug development, is well-positioned to benefit from this trend. The global personalized medicine market is projected to reach $2.4 trillion by 2032, growing at a CAGR of 11.2% from 2023. This growth is driven by the increasing availability of genomic data and the development of targeted therapies.
- Growth opportunity 2: Increasing Demand for Biopharmaceuticals: The global biopharmaceutical market is experiencing significant growth, driven by the increasing prevalence of chronic diseases and the development of novel therapies. BBH's focus on companies involved in the development and production of drugs based on genetic analysis aligns with this trend. The global biopharmaceutical market is projected to reach $810 billion by 2030, growing at a CAGR of 8.3% from 2023. This growth is driven by the increasing demand for innovative therapies and the aging global population.
- Growth opportunity 3: Expansion of Diagnostic Equipment Market: The diagnostic equipment market is experiencing growth, driven by the increasing demand for early and accurate disease detection. BBH's exposure to companies involved in the manufacturing of diagnostic equipment positions it to benefit from this trend. The global diagnostic equipment market is projected to reach $110 billion by 2027, growing at a CAGR of 6.2% from 2022. This growth is driven by the increasing prevalence of chronic diseases and the development of new diagnostic technologies.
- Growth opportunity 4: Regulatory Approvals for New Therapies: Regulatory approvals for new therapies represent a significant growth catalyst for companies within the biotechnology sector. BBH's focus on companies involved in drug development positions it to benefit from successful regulatory outcomes. The FDA's approval process for new drugs is becoming more streamlined, which could accelerate the development and commercialization of innovative therapies. This is an ongoing opportunity.
- Growth opportunity 5: Strategic Acquisitions and Partnerships: Strategic acquisitions and partnerships within the biotechnology sector can drive growth and innovation. BBH's exposure to leading biotech companies positions it to benefit from these types of transactions. Companies are increasingly looking to acquire or partner with smaller biotech firms to gain access to new technologies and therapies. This is an ongoing opportunity.
What Are BBH's Competitive Advantages?
- Index Tracking: BBH benefits from tracking a well-established index (MVIS US Listed Biotech 25 Index), providing a clear and transparent investment strategy.
- Brand Recognition: VanEck is a well-known and respected investment management firm, which enhances the credibility of BBH.
- Specialized Focus: BBH's focus on the biotechnology sector provides a specialized investment option that is not readily available through broader market ETFs.
- Low Expense Ratio: BBH's expense ratio is competitive with other ETFs in the biotechnology sector.
What Does BBH Do?
VanEck Biotech ETF (BBH) was created to provide investors with a focused investment tool that tracks the performance of the leading companies in the biotechnology industry. The ETF operates by seeking to replicate, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR). This index is specifically designed to capture the overall performance of companies actively engaged in the development, production, marketing, and sales of drugs that are based on genetic analysis, as well as those involved in the manufacturing of diagnostic equipment. BBH's investment strategy centers around holding a portfolio of stocks that mirror the composition of the MVBBHTR index. This includes companies that are at the forefront of biotechnological innovation, from established pharmaceutical giants to emerging biotech firms. By focusing on these key players, BBH aims to provide investors with exposure to the potential growth and advancements within the biotech sector. The ETF's holdings are weighted to reflect the index, ensuring that the fund's performance closely aligns with the index's movements. As an ETF, BBH offers investors the benefits of diversification within the biotech industry, combined with the liquidity and transparency of an exchange-traded product. The fund is designed to be a convenient and efficient way for investors to gain exposure to the biotech sector without the need to individually select and manage a portfolio of biotech stocks. BBH is managed by VanEck, a well-established investment management firm with a long history of offering specialized investment products.
What Products and Services Does BBH Offer?
- Replicates the MVIS US Listed Biotech 25 Index.
- Invests in companies involved in the development and production of drugs based on genetic analysis.
- Invests in companies involved in the marketing and sales of drugs based on genetic analysis.
- Invests in companies involved in the manufacturing of diagnostic equipment.
- Provides investors with targeted exposure to the biotechnology sector.
- Offers diversification within the biotech industry through a single investment vehicle.
- Trades on major exchanges, providing liquidity and transparency.
How Does BBH Make Money?
- Tracks the performance of the MVIS US Listed Biotech 25 Index.
- Generates revenue through management fees charged to investors.
- Rebalances its portfolio to maintain alignment with the index.
- Offers investors a convenient way to access the biotech market.
What Industry Does BBH Operate In?
VanEck Biotech ETF (BBH) operates within the asset management industry, specifically focusing on the biotechnology sector. The biotechnology industry is characterized by rapid innovation, high growth potential, and significant regulatory oversight. Market trends include advancements in genomics, personalized medicine, and gene editing technologies. The competitive landscape includes other specialized ETFs and mutual funds that focus on the healthcare and biotechnology sectors. BBH differentiates itself by tracking the MVIS US Listed Biotech 25 Index, which provides a focused exposure to leading companies in the biotech space.
Who Are BBH's Key Customers?
- Retail investors seeking exposure to the biotechnology sector.
- Institutional investors looking for a targeted investment vehicle.
- Financial advisors seeking to diversify client portfolios.
- Hedge funds and other sophisticated investors.
How VanEck Biotech ETF Is Valued
VanEck Biotech ETF carries a market capitalization of $457M, placing it in the small-cap category. Relative to its peer group, BBH's quantitative score of 47/100 is roughly in line with the peer average of 46/100.
Key Financial Metrics
Return on equity for VanEck Biotech ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. BBH trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
BBH Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the biotechnology sector.
- Replicates a well-established index (MVIS US Listed Biotech 25 Index).
- Managed by a reputable investment management firm (VanEck).
- Provides diversification within the biotech industry.
Bear Case
- Subject to the volatility of the biotechnology sector.
- Performance is dependent on the performance of the underlying index.
- Absence of dividend yield may not appeal to all investors.
- Concentrated exposure to a specific sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
BBH Latest News
No recent news available for BBH.
BBH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BBH.
Price Targets
Wall Street price target analysis for BBH.
BBH MoonshotScore
What does this score mean?
The MoonshotScore rates BBH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Common Questions About BBH (Financial Services)
What does the AI Score mean for BBH?
BBH holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. VanEck Biotech ETF (BBH) aims to mirror the MVIS US Listed Biotech 25 Index, focusing on companies involved in genetic analysis-based drug development and diagnostic equipment. The ETF provides …
What does VanEck Biotech ETF do?
VanEck Biotech ETF (BBH) seeks to replicate the performance of the MVIS US Listed Biotech 25 Index. This index tracks the performance of the 25 largest and most liquid US-listed companies in the biotechnology industry. BBH invests in these companies, providing investors with a convenient way to gain exposure to the biotech sector.
What are the main risks for BBH?
The main risks for VanEck Biotech ETF (BBH) include regulatory hurdles, clinical trial failures, and competitive pressures within the biotechnology industry. Regulatory approvals are essential for the commercialization of new therapies, and delays or rejections can negatively impact the performance of biotech companies. Clinical trial failures can also lead to significant losses for companies developing new drugs.
How does VanEck Biotech ETF adapt to regulatory changes in the biotech industry?
VanEck Biotech ETF adapts to regulatory changes by closely monitoring the regulatory landscape and adjusting its investment strategy accordingly. The ETF's investment team stays informed about changes in government regulations and healthcare policies that could impact the biotechnology sector. This includes monitoring the FDA's approval process for new drugs, changes in reimbursement policies, and other regulatory developments.
What are the implications of interest rate changes on VanEck Biotech ETF's performance?
Changes in interest rates can have several implications for VanEck Biotech ETF's performance. Higher interest rates can increase the cost of capital for biotech companies, potentially slowing down investment in research and development. This could negatively impact the growth prospects of these companies and, consequently, the ETF's performance.
What are the key factors to evaluate for BBH?
VanEck Biotech ETF (BBH) holds an AI score of 47/100 (low). VanEck Biotech ETF (BBH) presents a targeted investment opportunity in the biotechnology sector, driven by innovation in genetic analysis and drug development. Not financial advice.
How frequently does BBH data refresh on this page?
BBH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BBH's recent stock price performance?
VanEck Biotech ETF (BBH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the biotechnology sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BBH overvalued or undervalued right now?
VanEck Biotech ETF (BBH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for BBH. Information is based on available data and may be subject to change.